冠昊生物
(300238)
| 流通市值：28.34亿 | | | 总市值：29.36亿 |
| 流通股本：2.65亿 | | | 总股本：2.75亿 |
| 利润表 |
| 报告期 | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 |
| 营业总收入 | 250,582,625.52 | 174,516,375.45 | 93,444,027.57 | 387,749,767.9 |
| 营业总成本 | 237,418,751.81 | 161,974,132.06 | 83,859,027.31 | 358,622,829.07 |
| 其他经营收益 | | | | |
| 营业利润 | 14,355,883.36 | 13,140,180.72 | 10,701,296.25 | 30,453,513.15 |
| 利润总额 | 15,114,973.79 | 13,745,891.51 | 10,513,667.65 | 27,280,561.83 |
| 净利润 | 6,770,937.28 | 7,653,728.99 | 7,202,467.67 | 14,787,270.04 |
| 每股收益 | | | | |
| 其他综合收益 | -249,353.6 | -191,767.96 | -112,033.94 | -125,555.44 |
| 综合收益总额 | 6,521,583.68 | 7,461,961.03 | 7,090,433.73 | 14,661,714.6 |
| 资产负债表 |
| 报告期 | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 |
| 流动资产: | | | | |
| 流动资产合计 | 379,881,093.35 | 297,314,828.49 | 307,842,566.62 | 325,608,234.99 |
| 非流动资产: | | | | |
| 非流动资产合计 | 477,400,357.61 | 482,070,808.89 | 479,380,405.23 | 480,924,177.2 |
| 资产总计 | 857,281,450.96 | 779,385,637.38 | 787,222,971.85 | 806,532,412.19 |
| 流动负债: | | | | |
| 流动负债合计 | 129,379,192.73 | 144,569,947.34 | 153,599,890.85 | 188,540,549.12 |
| 非流动负债: | | | | |
| 非流动负债合计 | 138,388,127.27 | 139,536,802.48 | 138,715,720.74 | 130,174,936.54 |
| 负债合计 | 267,767,320 | 284,106,749.82 | 292,315,611.59 | 318,715,485.66 |
| 所有者权益(或股东权益): | | | | |
| 归属于母公司股东权益合计 | 680,938,838.7 | 583,115,533.9 | 580,117,758.49 | 570,067,516.98 |
| 股东权益合计 | 589,514,130.96 | 495,278,887.56 | 494,907,360.26 | 487,816,926.53 |
| 负债和股东权益合计 | 857,281,450.96 | 779,385,637.38 | 787,222,971.85 | 806,532,412.19 |
| 现金流量表 |
| 报告期 | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 |
| 经营活动产生的现金流量: | | | | |
| 经营活动现金流入小计 | 280,670,745.42 | 192,065,106.35 | 104,154,662.17 | 456,130,353.59 |
| 经营活动现金流出小计 | 289,497,378.12 | 198,836,210.23 | 117,978,802.31 | 384,656,557.83 |
| 经营活动产生的现金流量净额 | -8,826,632.7 | -6,771,103.88 | -13,824,140.14 | 71,473,795.76 |
| 投资活动产生的现金流量: | | | | |
| 投资活动现金流入小计 | 2,384,487.15 | 1,580,122.15 | 1,579,662.15 | 3,177,691.34 |
| 投资活动现金流出小计 | 21,215,009.73 | 16,724,377.98 | 11,898,993.69 | 39,368,477.33 |
| 投资活动产生的现金流量净额 | -18,830,522.58 | -15,144,255.83 | -10,319,331.54 | -36,190,785.99 |
| 筹资活动产生的现金流量: | | | | |
| 筹资活动现金流入小计 | 109,469,954.51 | 13,219,958.77 | 11,269,958.77 | 51,114,800 |
| 筹资活动现金流出小计 | 19,088,247.9 | 5,788,219.95 | 3,265,789.99 | 30,096,410.44 |
| 筹资活动产生的现金流量净额 | 90,381,706.61 | 7,431,738.82 | 8,004,168.78 | 21,018,389.56 |
| 汇率变动对现金及现金等价物的影响 | -800,248.04 | -359,596.12 | -241,730.26 | -182,486.94 |
| 现金及现金等价物净增加额 | 61,924,303.29 | -14,843,217.01 | -16,381,033.16 | 56,118,912.39 |
| 期末现金及现金等价物余额 | 222,527,015.79 | 145,759,495.49 | 144,221,679.34 | 160,602,712.5 |
| 补充资料: | | | | |
| 现金及现金等价物的净增加额 | - | -14,843,217.01 | - | 56,118,912.39 |